Abstract
Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 547-550 |
| Number of pages | 4 |
| Journal | Current Pharmaceutical Design |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 1 2017 |
Fingerprint
Keywords
- Age-related eye disease study (AREDS)
- Age-related macular degeneration (AMD)
- Age-related maculopathy susceptibility 2 (ARMS2)
- Complement factor H (CFH)
- Pharmacogenetics
- Vascular endothelial growth factor (VEGF)
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
Cite this
Hot topics in pharmacogenetics of age-related macular degeneration. / Schwartz, Stephen; Brantley, Milam A.; Kovach, Jaclyn; Grzybowski, Andrzej.
In: Current Pharmaceutical Design, Vol. 23, No. 4, 01.02.2017, p. 547-550.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hot topics in pharmacogenetics of age-related macular degeneration
AU - Schwartz, Stephen
AU - Brantley, Milam A.
AU - Kovach, Jaclyn
AU - Grzybowski, Andrzej
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.
AB - Age-related macular degeneration (AMD) is a leading cause of irreversible visual loss and is primarily treated with nutritional supplementation as well as with anti-vascular endothelial growth factor (VEGF) agents for certain patients with neovascular disease. AMD is a complex disease with both genetic and environmental risk factors. In addition, treatment outcomes from nutritional supplementation and anti-VEGF agents vary considerably. Therefore, it is reasonable to suspect that there may be pharmacogenetic influences on these treatments. Many series have reported individual associations with variants in complement factor H (CFH), age-related maculopathy susceptibility 2 (ARMS2), and other loci. However, at this time there are no validated associations. With respect to AMD, pharmacogenetics remains an intriguing area of research but is not helpful for routine clinical management.
KW - Age-related eye disease study (AREDS)
KW - Age-related macular degeneration (AMD)
KW - Age-related maculopathy susceptibility 2 (ARMS2)
KW - Complement factor H (CFH)
KW - Pharmacogenetics
KW - Vascular endothelial growth factor (VEGF)
UR - http://www.scopus.com/inward/record.url?scp=85018490770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018490770&partnerID=8YFLogxK
U2 - 10.2174/1381612822666161208114847
DO - 10.2174/1381612822666161208114847
M3 - Article
VL - 23
SP - 547
EP - 550
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 4
ER -